Woolsey Pharmaceuticals, Inc. articles

REAL is a phase 2a open-label study to assess preliminary safety, tolerability, and effect on clinical outcomes as well as neurodegeneration biomarkers of BRAVYL in patients with ALS.  

The study will enroll approximately 20 patients, all of whom will be treated with BRAVYL for 24 weeks.

Drug repurposing – uncovering new uses for already-approved medicines that could benefit patients facing a different need than originally intended – is bringing hope to millions of the desperately ill and their families.

This is especially true for those suffering from rare diseases – who can’t wait a dozen or more years for a new treatment to be discovered, developed, and made available.

Drug repurposing not only offers advantages over traditional de n